Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)
This study will use imaging to look at tumor response to erlotinib (Part I) and the combination of erlotinib and dalotuzumab (Part II).
Carcinoma, Non-small Cell Lung
DRUG: Comparator: erlotinib + dalotuzumab|DRUG: Comparator: erlotinib monotherapy
Validate imaging platform and molecular markers, FDG response at Weeks 1 and 3 following chemotherapy
Progression-free survival, overall survival, 3 months
This study will use imaging to look at tumor response to erlotinib (Part I) and the combination of erlotinib and dalotuzumab (Part II).